Go to
JCI Insight
Citations to this article
Evan M. Cale, … , Morgane Rolland, on behalf of the RV397 Study Group
Published March 17, 2020
Citation Information: J Clin Invest. 2020;130(6):3299-3304. https://doi.org/10.1172/JCI134395.
Citation Information: J Clin Invest. 2020;130(6):3299-3304. https://doi.org/10.1172/JCI134395.
Abstract
Infusion of the broadly neutralizing antibody VRC01 has been evaluated in individuals chronically infected with HIV-1. Here, we studied how VRC01 infusions affected viral rebound after cessation of antiretroviral therapy (ART) in 18 acutely treated and durably suppressed individuals. Viral rebound occurred in all individuals, yet VRC01 infusions modestly delayed rebound and participants who showed a faster decay of VRC01 in serum rebounded more rapidly. Participants with strains most sensitive to VRC01 or with VRC01 epitope motifs similar to known VRC01-susceptible strains rebounded later. Upon rebound, HIV-1 sequences were indistinguishable from those sampled at diagnosis. Across the cohort, participant-derived Env showed different sensitivity to VRC01 neutralization (including 2 resistant viruses), yet neutralization sensitivity was similar at diagnosis and after rebound, indicating the lack of selection for VRC01 resistance during treatment interruption. Our results showed that viremia rebounded despite the absence of HIV-1 adaptation to VRC01 and an average VRC01 trough of 221 μg/mL. Although VRC01 levels were insufficient to prevent a resurgent infection, knowledge that they did not mediate Env mutations in acute-like viruses is relevant for antibody-based strategies in acute infection.
Authors
Evan M. Cale, Hongjun Bai, Meera Bose, Michael A. Messina, Donn J. Colby, Eric Sanders-Buell, Bethany Dearlove, Yifan Li, Emily Engeman, Daniel Silas, Anne Marie O’Sullivan, Brendan Mann, Suteeraporn Pinyakorn, Jintana Intasan, Khunthalee Benjapornpong, Carlo Sacdalan, Eugène Kroon, Nittaya Phanuphak, Robert Gramzinski, Sandhya Vasan, Merlin L. Robb, Nelson L. Michael, Rebecca M. Lynch, Robert T. Bailer, Amélie Pagliuzza, Nicolas Chomont, Amarendra Pegu, Nicole A. Doria-Rose, Lydie Trautmann, Trevor A. Crowell, John R. Mascola, Jintanat Ananworanich, Sodsai Tovanabutra, Morgane Rolland, on behalf of the RV397 Study Group
Citation information
Citations to this article (27)
| Title and authors | Publication | Year |
|---|---|---|
|
Incompletely closed HIV-1CH040 envelope glycoproteins resist broadly neutralizing antibodies while mediating efficient HIV-1 entry
Parthasarathy D, Pickthorn S, Ahmed S, Mazurov D, Jeffy J, Shukla RK, Sharma A, Herschhorn A |
npj Viruses | 2025 |
|
Assessing bnAb potency in the context of HIV-1 envelope conformational plasticity
Foulkes C, Friedrich N, Ivan B, Stiegeler E, Magnus C, Schmidt D, Karakus U, Weber J, Günthard HF, Pasin C, Rusert P, Trkola A |
PLOS Pathogens | 2025 |
|
SIV monoclonal antibody administration spanning treatment interruption in macaques delays viral rebound and selects escape variants
King HA, Brammer D, Lewitus E, Fennessey CM, Manalang KM, Shrader HR, Andrew S, Kuri P, Lind M, Pham P, Sanders-Buell E, Bai H, Mason R, Song K, McCarthy E, Helmold Hait S, Todd JP, Pegu A, Foulds KE, Lifson JD, Keele BF, Rolland M, Roederer M, Bolton DL |
Proceedings of the National Academy of Sciences of the United States of America | 2025 |
|
Clinical trials of broadly neutralizing monoclonal antibodies in people living with HIV – a review
Mahomed S, Pillay K, Hassan-Moosa R, Galvão BP, Burgers WA, Moore PL, Rose-Abrahams M, Williamson C, Garrett N |
AIDS Research and Therapy | 2025 |
|
Autologous neutralizing antibody responses after antiretroviral therapy in acute and early HIV-1.
Gregory Whitehill, Jaimy Joy, Francesco Marino, Ryan Krause, Suvadip Mallick, Kyewon Park, John Carey, Rebeccah Hoh, Heather Hartig, Vivian Pae, Sannidhi Sarvadhavabhatla, Sophia Donaire, Steven Deeks, Rebecca Lynch, Sulggi Lee, Katharine Bar |
Journal of Clinical Investigation | 2024 |
|
Prevention efficacy of the broadly neutralizing antibody VRC01 depends on HIV-1 envelope sequence features
Juraska M, Bai H, deCamp AC, Magaret CA, Li L, Gillespie K, Carpp LN, Giorgi EE, Ludwig J, Molitor C, Hudson A, Williamson BD, Espy N, Simpkins B, Rudnicki E, Shao D, Rossenkhan R, Edlefsen PT, Westfall DH, Deng W, Chen L, Zhao H, Bhattacharya T, Pankow A, Murrell B, Yssel A, Matten D, York T, Beaume N, Gwashu-Nyangiwe A, Ndabambi N, Thebus R, Karuna ST, Morris L, Montefiori DC, Hural JA, Cohen MS, Corey L, Rolland M, Gilbert PB, Williamson C, Mullins JI |
Proceedings of the National Academy of Sciences | 2024 |
|
HIResist: a database of HIV-1 resistance to broadly neutralizing antibodies.
Misra M, Jeffy J, Liao C, Pickthorn S, Wagh K, Herschhorn A |
Bioinformatics (Oxford, England) | 2024 |
|
The combination of three CD4-induced antibodies targeting highly conserved Env regions with a small CD4-mimetic achieves potent ADCC activity
Marchitto L, Richard J, Prévost J, Tauzin A, Yang D, Chiu T, Chen HC, Díaz-Salinas MA, Nayrac M, Benlarbi M, Beaudoin-Bussières G, Anand SP, Dionne K, Bélanger É, Chatterjee D, Medjahed H, Bourassa C, Tolbert WD, Hahn BH, Munro JB, Pazgier M, Smith AB III, Finzi A |
2024 | |
|
The Use of Broadly Neutralizing Antibodies (bNAbs) in HIV-1 Treatment and Prevention
Thavarajah JJ, Hønge BL, Wejse CM |
Viruses | 2024 |
|
Mosaic vaccine-induced antibody-dependent cellular phagocytosis associated with delayed HIV-1 viral load rebound post treatment interruption
Mdluli T, Slike BM, Curtis DJ, Shubin Z, Tran U, Li Y, Dussupt V, Mendez-Rivera L, Pinyakorn S, Stieh DJ, Tomaka FL, Schuitemaker H, Pau MG, Colby DJ, Kroon E, Sacdalan C, de Souza M, Phanupak N, Hsu DC, Ananworanich J, Ake JA, Trautmann L, Vasan S, Robb ML, Krebs SJ, Paquin-Proulx D, Rolland M |
Cell Reports | 2024 |
|
The combination of three CD4-induced antibodies targeting highly conserved Env regions with a small CD4-mimetic achieves potent ADCC activity
Marchitto L, Richard J, Prévost J, Tauzin A, Yang D, Chiu TJ, Chen HC, Díaz-Salinas MA, Nayrac M, Benlarbi M, Beaudoin-Bussières G, Anand SP, Dionne K, Bélanger É, Chatterjee D, Medjahed H, Bourassa C, Tolbert WD, Hahn BH, Munro JB, Pazgier M, Smith AB III, Finzi A |
Journal of Virology | 2024 |
|
Structure-Based Identification of Natural-Product-Derived Compounds with Potential to Inhibit HIV-1 Entry
Ugwu-Korie N, Quaye O, Wright E, Languon S, Agyapong O, Broni E, Gupta Y, Kempaiah P, Kwofie SK |
Molecules (Basel, Switzerland) | 2023 |
|
High monoclonal neutralization titers reduced breakthrough HIV-1 viral loads in the Antibody Mediated Prevention trials.
Reeves DB, Mayer BT, deCamp AC, Huang Y, Zhang B, Carpp LN, Magaret CA, Juraska M, Gilbert PB, Montefiori DC, Bar KJ, Cardozo-Ojeda EF, Schiffer JT, Rossenkhan R, Edlefsen P, Morris L, Mkhize NN, Williamson C, Mullins JI, Seaton KE, Tomaras GD, Andrew P, Mgodi N, Ledgerwood JE, Cohen MS, Corey L, Naidoo L, Orrell C, Goepfert PA, Casapia M, Sobieszczyk ME, Karuna ST, Edupuganti S |
Nature Communications | 2023 |
|
Ultrasensitive quantification of HIV-1 cell-to-cell transmission in primary human CD4+ T cells measures viral sensitivity to broadly neutralizing antibodies
Mazurov D, Herschhorn A |
mBio | 2023 |
|
Broadly neutralizing antibodies targeting HIV: Progress and challenges
Paneerselvam N, Khan A, Lawson BR |
Clinical Immunology | 2023 |
|
Development of Screening Assays for Use of Broadly Neutralizing Antibodies in People Living with HIV
Lynch RM, Bar KJ |
Current opinion in HIV and AIDS | 2023 |
|
HIV-1 Reservoir Persistence and Decay: Implications for Cure Strategies
E Kreider, K Bar |
Current HIV/AIDS Reports | 2022 |
|
HIV-1 infections with multiple founders associate with the development of neutralization breadth
E Lewitus, S Townsley, Y Li, G Donofrio, B Dearlove, H Bai, E Sanders-Buell, A OSullivan, M Bose, H Kibuuka, L Maganga, S Nitayaphan, F Sawe, L Eller, N Michael, V Polonis, J Ake, S Vasan, M Robb, S Tovanabutra, S Krebs, M Rolland, R Swanstrom |
PLoS pathogens | 2022 |
|
Safety and tolerability of AAV8 delivery of a broadly neutralizing antibody in adults living with HIV: a phase 1, dose-escalation trial
J Casazza, E Cale, S Narpala, G Yamshchikov, E Coates, C Hendel, L Novik, L Holman, A Widge, P Apte, I Gordon, M Gaudinski, M Conan-Cibotti, B Lin, M Nason, O Trofymenko, S Telscher, S Plummer, D Wycuff, W Adams, J Pandey, A McDermott, M Roederer, A Sukienik, S ODell, J Gall, B Flach, T Terry, M Choe, W Shi, X Chen, F Kaltovich, K Saunders, J Stein, N Doria-Rose, R Schwartz, A Balazs, D Baltimore, G Nabel, R Koup, B Graham, J Ledgerwood, J Mascola, C Andrews, A Arthur, S Awan, A Beck, E Burch, M Florez, N Berkowitz, E Boritz, K Carlton, C Cartagena, C Carter, G Chen, P Costner, J Cunningham, D Douek, A Eshun, C Evans, R Hicks, K Houser, J Jones, B Larkin, L Le, F Mendoza, S Migueles, J Misasi, T Nguyen, A Ola, K Parker, I Pittman, L Requilman, R Rothwell, G Schieber, J Saunders, S Sitar, C Tran, O Trofymenko, O Vasilenko, S Waheed, L Wang, X Wang, W Whalen, P Williams, R Wu, K Zephir |
Nature Medicine | 2022 |
|
Optimizing clinical dosing of combination broadly neutralizing antibodies for HIV prevention
B Mayer, A deCamp, Y Huang, J Schiffer, R Gottardo, P Gilbert, D Reeves, J Gallo |
PLoS computational biology | 2022 |
|
Acute HIV-1 infection viremia associate with rebound upon treatment interruption.
Mdluli T, Li Y, Pinyakorn S, Reeves DB, Cardozo-Ojeda EF, Yates A, Intasan J, Tipsuk S, Phanuphak N, Sacdalan C, Colby DJ, Kroon E, Crowell TA, Thomas R, Robb ML, Ananworanich J, de Souza M, Phanuphak P, Stieh DJ, Tomaka FL, Trautmann L, Ake JA, Hsu DC, Francisco LV, Vasan S, Rolland M |
2022 | |
|
Enhancing HIV-1 Neutralization by Increasing the Local Concentration of Membrane-Proximal External Region-Directed Broadly Neutralizing Antibodies
Kim S, Filsinger Interrante MV, Kim PS |
Journal of virology | 2022 |
|
Monoclonal Antibodies as Long-Acting Products: What Are We Learning From Human Immunodeficiency Virus (HIV) and Coronavirus Disease 2019 (COVID-19)?
Caskey M, Kuritzkes DR |
Clinical Infectious Diseases | 2022 |
|
Antiviral Drug Discovery and Development
X Liu, P Zhan, L Menéndez-Arias, V Poongavanam |
2021 | |
|
Heightened resistance to host type 1 interferons characterizes HIV-1 at transmission and after antiretroviral therapy interruption
MV Gondim, S Sherrill-Mix, F Bibollet-Ruche, RM Russell, S Trimboli, AG Smith, Y Li, W Liu, AN Avitto, JC DeVoto, J Connell, AE Fenton-May, P Pellegrino, I Williams, E Papasavvas, JC Lorenzi, DB Salantes, F Mampe, MA Monroy, YZ Cohen, S Heath, MS Saag, LJ Montaner, RG Collman, JM Siliciano, RF Siliciano, LJ Plenderleith, PM Sharp, M Caskey, MC Nussenzweig, GM Shaw, P Borrow, KJ Bar, BH Hahn |
Science Translational Medicine | 2021 |
|
Can Broadly Neutralizing HIV-1 Antibodies Help Achieve an ART-Free Remission?
DC Hsu, JW Mellors, S Vasan |
Frontiers in immunology | 2021 |
|
Recent advances in immunotherapies against infectious diseases
Ramamurthy D, Nundalall T, Cingo S, Mungra N, Karaan M, Naran K, Barth S |
2020 |
Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)